BRD3 and leukemia: While BRD3/4 inhibition significantly impaired proliferation and survival of MLL-AF9 driven leukemia in both in vitro and in vivo studies, the involved targets did not seem to completely overlap with the MLL-AF9-induced oncogenic program.